Gut and mouth bacteria may predict who benefits from probiotics for gum disease

NCT ID NCT07718074

Not yet recruiting Disease control Sponsor: University of New Hampshire Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether a daily probiotic lozenge containing Limosilactobacillus reuteri can reduce inflammation and improve gum health in adults with severe periodontal disease. Researchers will also analyze participants' oral and gut bacteria to identify who is most likely to respond to the probiotic. The goal is to develop a more personalized approach to treating gum disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a probiotic lozenge containing two strains of Limosilactobacillus reuteri
What this could lead to: If successful, this could point toward a personalized probiotic approach to help manage severe gum disease by reducing inflammation and improving oral health.
What could go wrong: This is a relatively small, early-stage trial, and individual responses to probiotics vary widely. The results may not apply to everyone with gum disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIODONTAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIODONTAL DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.